PrecisCa
PrecisCa supports patients, their caregivers, and health care providers at every step of their cancer journeys from diagnosis to remission, with up-to-date education on the latest advancements in cancer care and access to leading specialists to analyze patient scenarios
Hematology
PrecisCa
Expert Panel Case Discussion: 64 y/o Male With a History of CLL Presents With Thrombocytopenia
- 31 views
- December 4, 2023
PrecisCa
The BRUIN Study: Pirtobrutinib in Mantle Cell Lymphoma
FEATURING
Manali Kamdar
- 190 views
- June 7, 2023
PrecisCa
Treatment Approach for Older Patients With Mantle Cell Lymphoma: A Discussion of the SHINE Trial
FEATURING
Manali Kamdar
- 215 views
- June 7, 2023
PrecisCa
The POLARIX Trial: Polatuzumab With R-CHP in DLBCL
FEATURING
Manali Kamdar
- 247 views
- June 7, 2023
PrecisCa
Updates From the ECHELON-1 Trial Utilizing Brentuximab in Hodgkin’s Lymphoma
FEATURING
Manali Kamdar
- 88 views
- June 7, 2023
PrecisCa
Agents Under Investigation to Treat TP53m AML
FEATURING
Daniel Pollyea
- 163 views
- March 8, 2023
- 1
PrecisCa
Latest Updates on the Use of Targeted Agents in R/R FLT3+ AML
FEATURING
Daniel Pollyea
- 15 views
- March 8, 2023
PrecisCa
Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Trial
FEATURING
Ajay Nooka
- 734 views
- March 8, 2023
- 3
PrecisCa
ASCT in Newly Diagnosed Multiple Myeloma: Results From the DETERMINATION Trial
FEATURING
Ajay Nooka
- 129 views
- March 8, 2023
PrecisCa
Heme Tumor Board: 60 y/o Female Presents With Newly Diagnosed CD30- PTCL and HLH
- 73 views
- December 16, 2022
PrecisCa
What Is Hepatosplenic T-Cell Lymphoma and How Do You Treat It?
FEATURING
Jeremy Abramson
- 39 views
- December 15, 2022
PrecisCa
What Is Nodular Lymphocyte Predominant Hodgkin Lymphoma and How Do You Treat It?
FEATURING
Jeremy Abramson
- 38 views
- December 15, 2022
- 1
PrecisCa
How Do the Recently Approved and Likely Soon to Be Approved Agents Change the Management of Chronic GVHD?
FEATURING
Yi-Bin Chen
- 13 views
- December 15, 2022
PrecisCa
How Do You Manage Steroid-Refractory Acute GVHD and How Do Current Trials Hope to Improve Upon the Current Standard Therapy?
FEATURING
Yi-Bin Chen
- 6 views
- December 15, 2022
PrecisCa
Is Post-Transplant Cyclophosphamide the New Standard for GVHD Prevention?
FEATURING
Yi-Bin Chen
- 11 views
- December 15, 2022
PrecisCa
FLT3-Mutated AML: Interpreting Recent Data on Maintenance TKI After ASCT
FEATURING
Yi-Bin Chen
- 198 views
- December 9, 2022
- 1
PrecisCa
Induction Therapy for Patients With High-Risk NDMM: When to Utilize Four-Drug Combinations Upfront?
FEATURING
Ajay Nooka
- 65 views
- September 15, 2022
